FindTrial
Sign In

The role of the endocannabinoidsystem and the immune system in chronic pain - alterations in comparison to healthy volunteers and influence of pain treatment

The role of the endocannabinoidsystem and the immune system in chronic pain - alterations in comparison to healthy volunteers and influence of pain treatment

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
DRKS
Registry ID
DRKS00005954
Enrollment
125
Registered
2014-03-12
Start date
2011-09-02
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

R52.2

Interventions

Group 1: The aim of this study is to determine the endocannabinoid- and immune system in patients with chronic pain. All patients will receive study-independent standard treatment of the corresponding

Sponsors

Interdisziplinäre Schmerzambulanz und Tageskinik, LMU München, Klinikum Großhadern
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Patients with chronic nociceptive and/or neuropathic pain without medication or stable medication for at least 14 days

Exclusion criteria

Exclusion criteria: Pregnancy, psychological/mental disorder, addiction, glucocorticoid treatment

Design outcomes

Primary

MeasureTime frame
Before and after standard treatment: Pain level: NRS, Stresslevel: KAB, Cytokines: Immunassay, Endocannabinoids: Mass-spektrometry, T cells: Flow cytometry, mRNA-expression: RT-PCR—

Secondary

MeasureTime frame
Influences of routine standard pain treatment on the primary outcome parameters.—

Countries

Germany

Contacts

Public ContactShahnaz Christina Azad

Interdisziplinäre Schmerzambulanz und Tageskinik, LMU München, Klinikum Großhadern

sazad@med.uni-muenchen.de089-7095-4464

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Mar 18, 2026